Lonza Capacity Update July 2025: ADC

As the Antibody-Drug Conjugate (ADC) market continues its robust expansion, the demand for specialized manufacturing expertise is paramount. Lonza, a leading CDMO, offers a complete end-to- end solution that simplifies the value chain and accelerates the timeline to the clinic or the market. Leveraging our deep ADC expertise and experience we successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.